Emerging in the arena of obesity therapy, retatrutide represents a different strategy. Different from many current medications, retatrutide functions as a double agonist, concurrently engaging both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. The dual activation encourages multiple beneficial eff